Two-year outcome after biodegradable polymer sirolimus- and biolimus- eluting coronary stents: From the randomized SORT OUT VII trial

AIMS: The SORT OUT VII trial compared the thin-strut cobalt-chromium sirolimus-eluting Orsiro stent with a slow polymer degradation and the thicker-strut stainless steel biolimus-eluting Nobori stent with a moderate-term polymer degradation in an all-comer patient population.

METHODS AND RESULTS: The 2-year pre-specified endpoint target lesion failure did not differ significantly between the sirolimus-eluting stent: 6.7% and the biolimus-eluting stent: 7.0% (rate ratio (RR) 0.94, 95% confidence interval (CI) 0.70-1.28). Definite stent thrombosis were numerically lower in the sirolimus-eluting stent group (0.8%) compared to the biolimus-eluting stent group (1.4%) (RR 0.56, 95% CI 0.26-1.21), which largely was attributable to a lower risk of definite stent thrombosis within 1 year: 0.4% versus 1.2% (RR 0.33, 95% CI 0.12-0.92), whereas risk of very late definite stent thrombosis was similar in the two groups (0.4% versus 0.2%, RR 1.68, 95% CI 0.40-7.03).

CONCLUSIONS: In an all-comer patient population, 2-year target lesions failure was similar for the sirolimus-eluting Orsiro stent and the biolimus-eluting Nobori stent.